Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients

General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre‐existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuznetsova, Anna, Lebedev, Aleksey, Gromov, Konstantin, Kazennova, Elena, Zazzi, Maurizio, Incardona, Francesca, Sönnerborg, Anders, Bobkova, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813671/
https://www.ncbi.nlm.nih.gov/pubmed/35140966
http://dx.doi.org/10.1002/ccr3.5373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813671/
https://www.ncbi.nlm.nih.gov/pubmed/35140966
http://dx.doi.org/10.1002/ccr3.5373

Ejemplares similares